Physician profile
Whitney Simons
NPI 1760190557
$4,789.01
in general payments reported to CMS, 2019-2025
26 companies · $2,685 in 2025
The $2,685 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,229 · 2024: $875 · 2025: $2,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,691 · Travel and Lodging: $942 · Education: $99.99 · Debt Forgiveness: $55.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,691.16 |
| Travel and Lodging | $942.10 |
| Education | $99.99 |
| Debt Forgiveness | $55.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $836.49 | 2023 | Linq II |
| Impulse Dynamics (USA) INC. | $719.98 | 2025 | Optimizer |
| Pfizer INC. | $379.73 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $358.83 | 2024-2025 | |
| Abiomed | $336.43 | 2024-2025 | Impella |
| Merck Sharp & Dohme LLC | $326.33 | 2023-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $302.51 | 2024-2025 | Camzyos, Eliquis |
| Bridgebio Pharma, INC. | $296.75 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $164.28 | 2024-2025 | Uptravi, Opsumit |
| Heartflow, INC. | $160.49 | 2025 | |
| Inspire Medical Systems, INC. | $145.29 | 2024 | Inspire |
| Boston Scientific Corporation | $128.56 | 2024-2025 | Watchman Flx, Watchman |
| Alnylam Pharmaceuticals INC. | $109.10 | 2025 | Amvuttra, Onpattro |
| Amgen INC. | $100.01 | 2023-2025 | Repatha, Repatha |
| Novo Nordisk INC | $72.00 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $55.76 | 2023 | |
| Scpharmaceuticals INC. | $48.10 | 2024 | |
| Biosense Webster, INC. | $44.19 | 2023 | Carto 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.06 | 2025 | Jardiance |
| Cvrx, INC. | $37.79 | 2024 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $36.01 | 2023 | Xarelto |
| Tactile Systems Technology INC | $25.22 | 2025 | Flexitouch Plus, Nimbl |
| Azurity Pharmaceuticals, INC. | $18.25 | 2024 | Edarbi |
| Lilly USA, LLC | $17.74 | 2025 | Zepbound, Mounjaro |
| Kiniksa Pharmaceuticals International, Plc | $15.79 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $15.32 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Simons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.